Navigation Links
Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
Date:11/5/2007

CHAPEL HILL, N.C., and VALAIS, Switzerland, Nov. 5 /PRNewswire/ -- Lantibio, Inc. and TRB Chemedica announced today the signing of a licensing agreement with a subsidiary of Alcon, Inc. (NYSE: ACL) for the US development, marketing, and manufacture of a Dry Eye Syndrome product. The product consists of a TRB patented formulation containing sodium hyaluronate and is currently being studied in the US under an IND by a subsidiary of Lantibio. An ongoing multi-center Phase III pivotal study is being conducted under the FDA's Special Protocol Assessment program. Lantibio expects to file an NDA in 2008 for the product as a treatment for Dry Eye Syndrome.

In Dry Eye Syndrome, it is hypothesized that the product, administered via ocular instillation will hydrate the surface of the eye preventing dryness and long-term ocular injury. Sodium hyaluronate is a known natural molecule with viscoelastic properties that in preparation with specific ions and chelators, lubricates the eye and hydrates the ocular surface.

Under the terms of the agreement, Lantibio will conduct the development program and filing of the NDA, while Alcon will assume responsibility for subsequent marketing, sales and manufacturing for the US market. Terms of the agreement include up-front and development milestone payments, as well as royalties to be paid to Lantibio and TRB by Alcon on sales of the approved product.

"We believe this product will bring significant relief to patients with Dry Eye Syndrome and look forward to completing our clinical study and to filing an NDA with the FDA for approval in the US," said Andrew Schiermeier, Ph.D., Chief Executive Officer of Lantibio, Inc. "We are delighted by this agreement, and could not hope fo
'/>"/>

SOURCE Lantibio, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Interventional cardiologist Tony Farah, MD, and his ... Cardiovascular Institute have helped pioneer many breakthroughs in ... over the past three decades, from new disease-fighting medications ... artery stent implantation. , Today, AGH officials announced that ... in the study of a novel, first-of-its kind investigational ...
(Date:5/20/2013)... 2013 In Early 2013, Dr. ... biotoxin related illnesses , announced his vision for creating ... advance his protocol for treating Chronic Inflammatory Response Syndrome ... physician to achieve certification in the Shoemaker Protocol. ... practice the Shoemaker Protocol in other parts of the ...
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
Breaking Biology Technology:Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3
... ... Safety Solutions Continues to Accelerate., , ... (PRWEB) June 22, 2010 -- iCardiac Technologies, Inc. , a ... top 20 pharmaceutical companies have recently selected iCardiac as a preferred vendor. iCardiac ...
... 21 A global research team led by scientists ... new study in the Proceedings of the National Academy of ... genome. Lead author, Ewen Kirkness , Ph.D., JCVI, directed ... of the genome was then conducted by a large international ...
... 21 Dyadic International, Inc. (Pink Sheets: DYAI), ... addresses the needs of the multi-billion dollar biofuels market ... biomass into ethanol and other forms of alternative energy, ... firm, The Abraham Group, to provide strategic advice and ...
Cached Biology Technology:Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 3Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4
(Date:5/17/2013)... day, insects provide the white noise of the South, but ... year, the Southern air hangs heavy from the humidity and ... more than 140 species of frogs, toads and salamanders, is ... the ponds and swamps are the auditorium for their symphonic ... and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... all ages will celebrate the science and technology ... daily lives during the inaugural Atlanta Science Festival, ... from local museums, corporations, K-12 schools and universities, ... events for children and adults at venues across ... , The annual Atlanta Science Festival is ...
(Date:5/17/2013)... Shenzhen, China---- Why Tibetan antelope can live at ... a collaborative research published in Nature Communications ... institutes provide evidence that some genetic factors may ... highland environments. The data in this work will ... and the biology of other ruminant species. , ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4First Atlanta Science Festival set for 2014 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... gibbons, arboreal primates that inhabit the jungles of Southeast Asia, ... in the genomes of all other primates, including humans. This ... approximately 25 million years ago. Their results are reported ... Research . , Agouti signaling protein ( ASIP ) was ...
... two novel genes within the tumors of women with early ... and are not at risk for early relapse or cancer-related ... April 1 issue of Clinical Cancer Research. , "The HOXB13 ... marker of relapse in hormone-receptor positive breast cancer treated with ...
... cancer-causing virus that was thought to be unimportant for its ... initiate an infection and to reproduce. , The study ... a protein it makes called p13. The protein is one ... done in laboratory-grown cells suggested that the virus could live ...
Cached Biology News:Major obesity gene is 'lost in the shuffle' 2Mayo Clinic study finds two genes predict outcome for breast cancer patients 2Cancer virus protein needed for successful infection 2